Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBP-213 in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT07891364Phase 1Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Nov 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1 trial of GBP-213 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Renji Hospital. Primary endpoint: Safety and tolerability of GBP-213. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
GBP-213
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07891364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891364.